Advertisement
INVA vs ROP
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INVA is a StrongBuy and ROP is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INVA’s FA Score shows that 0 FA rating(s) are green whileROP’s FA Score has 0 green FA rating(s).
- INVA’s FA Score: 0 green, 5 red.
- ROP’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INVA’s TA Score shows that 7 TA indicator(s) are bullish while ROP’s TA Score has 3 bullish TA indicator(s).
- INVA’s TA Score: 7 bullish, 4 bearish.
- ROP’s TA Score: 3 bullish, 6 bearish.
Price Growth
INVA (@Biotechnology) experienced а +4.72% price change this week, while ROP (@Packaged Software) price change was -3.50% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.69%. For the same industry, the average monthly price growth was +18.51%, and the average quarterly price growth was +31.06%.
The average weekly price growth across all stocks in the @Packaged Software industry was -1.69%. For the same industry, the average monthly price growth was +6.49%, and the average quarterly price growth was +11.73%.
Reported Earning Dates
INVA is expected to report earnings on Oct 29, 2025.
ROP is expected to report earnings on Oct 22, 2025.
Industries' Descriptions
@Biotechnology (+2.69% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Packaged Software (-1.69% weekly)Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.
| INVA | ROP | INVA / ROP | |
| Capitalization | 1.25B | 59.2B | 2% |
| EBITDA | 681K | 2.66B | 0% |
| Gain YTD | 15.043 | 5.953 | 253% |
| P/E Ratio | 51.97 | 43.46 | 120% |
| Revenue | 370M | 6.18B | 6% |
| Total Cash | 447M | 214M | 209% |
| Total Debt | 451M | 6.37B | 7% |
INVA | ROP | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 59 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 21 Undervalued | |
PROFIT vs RISK RATING 1..100 | 54 | 35 | |
SMR RATING 1..100 | 100 | 76 | |
PRICE GROWTH RATING 1..100 | 57 | 59 | |
P/E GROWTH RATING 1..100 | 100 | 58 | |
SEASONALITY SCORE 1..100 | 75 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ROP's Valuation (21) in the Industrial Conglomerates industry is in the same range as INVA (50) in the Pharmaceuticals Other industry. This means that ROP’s stock grew similarly to INVA’s over the last 12 months.
ROP's Profit vs Risk Rating (35) in the Industrial Conglomerates industry is in the same range as INVA (54) in the Pharmaceuticals Other industry. This means that ROP’s stock grew similarly to INVA’s over the last 12 months.
ROP's SMR Rating (76) in the Industrial Conglomerates industry is in the same range as INVA (100) in the Pharmaceuticals Other industry. This means that ROP’s stock grew similarly to INVA’s over the last 12 months.
INVA's Price Growth Rating (57) in the Pharmaceuticals Other industry is in the same range as ROP (59) in the Industrial Conglomerates industry. This means that INVA’s stock grew similarly to ROP’s over the last 12 months.
ROP's P/E Growth Rating (58) in the Industrial Conglomerates industry is somewhat better than the same rating for INVA (100) in the Pharmaceuticals Other industry. This means that ROP’s stock grew somewhat faster than INVA’s over the last 12 months.
| INVA | ROP | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 73% | N/A |
| Stochastic ODDS (%) | 1 day ago 72% | 2 days ago 54% |
| Momentum ODDS (%) | 1 day ago 65% | 2 days ago 41% |
| MACD ODDS (%) | 1 day ago 52% | 2 days ago 39% |
| TrendWeek ODDS (%) | 1 day ago 63% | 2 days ago 40% |
| TrendMonth ODDS (%) | 1 day ago 61% | 2 days ago 45% |
| Advances ODDS (%) | 1 day ago 67% | 15 days ago 46% |
| Declines ODDS (%) | 5 days ago 64% | 5 days ago 42% |
| BollingerBands ODDS (%) | 1 day ago 68% | 2 days ago 61% |
| Aroon ODDS (%) | 1 day ago 65% | 2 days ago 41% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BKMC | 104.41 | 0.48 | +0.46% |
| BNY Mellon US Mid Cap Core Equity ETF | |||
| NUSB | 25.27 | 0.03 | +0.12% |
| Nuveen Ultra Short Income ETF | |||
| MUSE | 49.48 | N/A | N/A |
| TCW Multisector Credit Income ETF | |||
| CGCP | 22.34 | -0.01 | -0.07% |
| Capital Group Core Plus Income ETF | |||
| IEDI | 55.34 | -0.16 | -0.28% |
| iShares U.S. Consumer Focused ETF | |||
INVA and
Correlation & Price change
A.I.dvisor indicates that over the last year, INVA has been loosely correlated with GBIO. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if INVA jumps, then GBIO could also see price increases.
| Ticker / NAME | Correlation To INVA | 1D Price Change % | ||
|---|---|---|---|---|
| INVA | 100% | +1.94% | ||
| GBIO - INVA | 39% Loosely correlated | -3.18% | ||
| SLNO - INVA | 37% Loosely correlated | +1.00% | ||
| KYMR - INVA | 36% Loosely correlated | +0.02% | ||
| DNLI - INVA | 36% Loosely correlated | -3.54% | ||
| SCPH - INVA | 36% Loosely correlated | -2.01% | ||
More | ||||
ROP and
Correlation & Price change
A.I.dvisor indicates that over the last year, ROP has been closely correlated with AME. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if ROP jumps, then AME could also see price increases.
| Ticker / NAME | Correlation To ROP | 1D Price Change % | ||
|---|---|---|---|---|
| ROP | 100% | +0.16% | ||
| AME - ROP | 75% Closely correlated | -1.44% | ||
| GGG - ROP | 71% Closely correlated | -0.58% | ||
| IEX - ROP | 69% Closely correlated | -0.33% | ||
| OTIS - ROP | 69% Closely correlated | +0.55% | ||
| NDSN - ROP | 68% Closely correlated | -1.08% | ||
More | ||||